Advertise here Publish your press releases here Sponsor BioPortfolio
Follow us on Twitter Sign up for daily news and research emails Contributors wanted

Search Results for "Ranbaxy Launches Atorvastatin In Us"

08:22 EDT 28th July 2014 | BioPortfolio

Matching Channels


Lipitor was the best selling drug in 2009, with the 2009 annual sales coming in at over $5m for its company, Pfizer Inc. Lipitor is the brand name for an atorvastatin calcium medication that is pres...

Matching News

The Curious Case Of The Ranbaxy-Teva Lipitor Deal; NY AG Reveals Hidden Provision

The New York Attorney General obtains a $300,000 settlement with Ranbaxy and Teva for their agreement not to challenge each other’s market exclusivity rights; the arrangement was part of a deal that...

Ranbaxy recalls Lipitor generic over dose error

India’s largest drugmaker Ranbaxy Laboratories (BSE: 500359) has recalled more than 64,000 bottles of the generic version of Pfizer’s cholesterol drug Lipitor (atorvastatin) in the USA.

Ranbaxy Recalls More Batches Of Suspect Lipitor Generic In U.S.

Ranbaxy Laboratories ordered a recall of two more batches of more than 64,000 bottles of its generic version of Pfizer's Lipitor (atorvastatin) cholesterol drug in the U.S. after finding a pill of tw...

Dr Reddy’s launches generic amlodipine/atorvastatin

Indian generics giant Dr Reddy’s announced on 27 March 2014 the launch of its generic amlodipine/atorvastatin tablets in the US.

Sun Looks to Phase Out Ranbaxy in US

Sun Pharmaceutical Industries plans to purchase Ranbaxy Lboratories from Daiichi Sankyo Ltd for $3.2 B in stock plus taking on $800 M in Ranbaxy debt as announced yesterday. The combined Sun and Ranba...

Ranbaxy now recalls 64,000 bottles of generic heart drug

Biospectrum Singapore: Ranbaxy Laboratories, which is already reeling under several regulatory rebukes owing to quality apprehensions,...

Ranbaxy hit with second generic Lipitor recall

India’s largest native generic drugmaker Ranbaxy has come under greater pressure this week after the US has again sent out a recall for one its medicines. The company, which is a unit of Japan’s D...

Update-Moody's: Daiichi Sankyo Will Benefit from Sun Pharma's Acquisition of Ranbaxy

Sun Pharmaceutical Industries Ltd (Sun Pharma) & Ranbaxy Laboratories Ltd (Ranbaxy)

Matching PubMed Articles

Impact of switching treatment from rosuvastatin to atorvastatin on rates of cardiovascular events.

Now that generic atorvastatin has become available, a process of switching from rosuvastatin to atorvastatin may occur and could persist until the patent on branded rosuvastatin expires. It is importa...

Formulation and evaluation of fixed-dose combination of bilayer gastroretentive matrix tablet containing atorvastatin as fast-release and atenolol as sustained-release.

The objective of the present study was to develop bilayer tablets of atorvastatin and atenolol that are characterized by initial fast-release of atorvastatin in the stomach and comply with the release...

Efficacy and Safety of Alternate Day Therapy With Atorvastatin and Fenofibrate Combination in Mixed Dyslipidemia: A Randomized Controlled Trial.

Introduction:The long half-life of atorvastatin and fenofibrate makes them suitable for alternate day therapy. Hence, we aimed to study the efficacy, safety, and cost-effectiveness of alternate day th...

Effects of atorvastatin on nitrate tolerance in diabetic rats.

Statins have been reported to show preventive effect on nitrate tolerance in normal rats, but there are no reports on their effect in diabetic animals. In this study, diabetes was induced in male wist...

Comparison of low-dose rosuvastatin with atorvastatin in lipid-lowering efficacy and safety in a high-risk pakistani cohort: an open-label randomized trial.

Background. Treatment of hyperlipidemia is helpful in both primary and secondary prevention of coronary heart disease and stroke. Aim. To compare lipid-lowering efficacy of rosuvastatin with atorvasta...

Search Whole site using Google

Search BioPortfolio:
Advertisement Advertisement